MA Nauck, RE Ratner, C Kapitza, R Berria, M … - Diabetes Care, 2009 - Am Diabetes Assoc RESULTS Significantly greater (P < 0.0001) reductions in A1C from a mean ± SD
baseline of 7.9 ± 0.7% were observed in all taspoglutide groups compared with
placebo after 8 weeks of treatment: –1.0 ± 0.1% (5 mg once weekly), ... Cited by 2 - Related articles - All 2 versions
DM Kendall, RM Cuddihy, RM Bergenstal - European Journal of Internal Medicine, 2009 - Elsevier Incretin-based therapies address the progressive nature of type 2 diabetes
mellitus, not only by addressing glucose control but also with weight-neutral
(ie, dipeptidyl peptidase–4 inhibitors sitagliptin and vildagliptin) and ... Cited by 4 - Related articles - All 38 versions
[CITATION] Voglibose Ph-3 Study Group: Voglibose for prevention of type 2 diabetes mellitus: a …
MA Bush, JE Matthews, EH De Boever, RL … - Diabetes Obes Metab, 2009 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 5 - Related articles - All 2 versions
[CITATION] for the LEAD 6 study group. Liraglutide once a day versus exenatide twice a day for type 2 …
A Bénardeau, J Benz, A Binggeli, D Blum, M … - Bioorganic & medicinal chemistry letters, 2009 - Elsevier Peroxisome Proliferator-Activated Receptors (PPAR) α, γ, and δ are three of
the 48 nuclear hormone receptors encoded in the human genome. 1 As
ligand-activated transcription factors they work in concert with ... Cited by 4 - Related articles - All 3 versions
Y Moritoh, K Takeuchi, M Hazama - Journal of Pharmacology and Experimental …, 2009 - ASPET Administration of an -glucosidase inhibitor, voglibose, increases the secretion
of glucagon-like peptide (GLP)-1, a key modulator of pancreatic islet hormone
secretion and glucose homeostasis. In the present study, novel mechanisms ... Cited by 4 - Related articles - All 3 versions
- ►leicestershirediabetes.org.uk [PDF] RR Henry, AM Lincoff, S Mudaliar, M Rabbia, … - The Lancet, 2009 - Elsevier In this double-blind study, patients with type 2 diabetes (either drug-naive or
pre-treated with ≤two oral agents) were enrolled from 47 sites in seven
countries. After a single-blind, 4–5-week placebo run-in period, 332 ... Cited by 4 - Related articles - All 23 versions
H Tenenbaum, S Behar, V Boyko, Y Adler, EZ … - Atherosclerosis, 2007 - Elsevier Development of insulin resistance (IR) and the progressive failure of the
pancreatic beta-cell function (BCF) may be important in the pathogenesis of type
2 diabetes. Influence of peroxisome proliferator-activated receptors ligand ... Cited by 5 - Related articles - All 14 versions
[CITATION] for The RECORD Study Group: Effect of the addition of rosiglitazone to metformin or …
